Vassiliki Karantza

20.7k citations

109 papers · 8.0k indexed · 6 hit papers · h-index 41

Oncology top 0.5%
- Cancer Immunotherapy and Biomarkers 54
- HER2/EGFR in Cancer Research 22
- Cancer Treatment and Pharmacology 15
- Cancer Cells and Metastasis 11
Cancer Research top 0.5%
- Breast Cancer Treatment Studies 21
- Cancer Genomics and Diagnostics 17
Immunology top 1%
Physiology top 1%
Pulmonary and Respiratory Medicine top 1%
- Advanced Breast Cancer Therapies 39
Epidemiology
- Autophagy in Disease and Therapy 12

Co-authors: Gursel Aktan Ning Chen Eileen White Peter Schmid Javier Cortés Sherene Loi Lajos Pusztai Laurence Buisseret
Cited by: Oncology Cancer Research Immunology
Journals: New England Journal of Medicine (1 paper)Journal of Clinical Oncology (15 papers)Genes & Development (1 paper)
Partner nations: United States Spain Germany

In The Last Decade

Vassiliki Karantza

105 papers receiving 7.8k citations

Hit Papers

6 papers align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2022 New England Journal of Medicine
2021 The Lancet Oncology
2020 Annals of Oncology
2018 Annals of Oncology
2016 Journal of Clinical Oncology
2011 Genes & Development

Peers

Countries citing papers authored by Vassiliki Karantza

Since Specialization

Citations

This map shows the geographic impact of Vassiliki Karantza's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vassiliki Karantza with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vassiliki Karantza more than expected).

Fields of papers citing papers by Vassiliki Karantza

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vassiliki Karantza. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vassiliki Karantza. The network helps show where Vassiliki Karantza may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Vassiliki Karantza, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Vassiliki Karantza Line = papers co-authored together Vassiliki Karantza links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	2758MO Updated results from a phase I/II study of gocatamig for small cell lung cancer (SCLC) and other neuroendocrine cancers Annals of Oncology ·Himisha Beltran,M.L. Johnson,Prantesh Jain,Erin L. Schenk,Rachel E. Sanborn,John A. Thompson,A. Dowlati,Hirva Mamdani,Rahul Aggarwal,K. Nathan Sankar,Satish Vaidya,Vassiliki Karantza,Aiguo Wang,Ann W. Gramza,A.J. Cooper	2025	0
2	2792TiP A phase Ib/II study of gocatamig (MK-6070; HPN328) and ifinatamab deruxtecan for relapsed/refractory extensive-stage small cell lung cancer (ES-SCLC) Annals of Oncology ·Jair Bar,J.C. Benítez Montañez,A.F. Navarro Mendivil,M. Gutierrez,M.L. Johnson,Christian Caglevic,N. Peled,Talia Shentzer Kutiel,J. Sands,C.I. Rojas,P.F. Simoes da Rocha,Efnan Algın,H. Udagawa,Ryo Ariyasu,T.M. Kim,C. Rathi,Vassiliki Karantza,Q. Liu,Ann W. Gramza,J-M. Sun	2025	0
3	Results from the randomized KEYNOTE-355 study of pembrolizumab plus chemotherapy for Asian patients with advanced TNBC npj Breast Cancer ·Seock‐Ah Im,Javier Cortés,David W. Cescon,Mastura Md Yusof,Hiroji Iwata,Norikazu Masuda,Toshimi Takano,Chiun‐Sheng Huang,Chi-Feng Chung,Koichiro Tsugawa,Yeon Hee Park,Koji Matsumoto,Kenichi Inoue,Ava Kwong,Sherene Loi,Wei Fu,Wilbur Pan,Vassiliki Karantza,Hope S. Rugo,Peter Schmid	2024	5
4	A Narrative Review of the Clinical, Humanistic, and Economic Value of Pembrolizumab-Based Immunotherapy for the Treatment of Breast and Gynecologic Cancers Oncology and Therapy ·Matthew Monberg,Steve Keefe,Vassiliki Karantza,Konstantinos Tryfonidis,Sarper Toker,Jaime Mejia,Robert Orlowski,Amin Haiderali,Vimalanand S. Prabhu,Gursel Aktan	2024	1
5	LBA21 KEYNOTE-756: Phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) + chemotherapy (chemo), followed by adjuvant pembro or pbo + endocrine therapy (ET) for early-stage high-risk ER+/HER2– breast cancer Annals of Oncology ·Fátima Cardoso,Heather L. McArthur,Peter Schmid,Javier Cortés,Nadia Harbeck,Melinda L. Telli,David W. Cescon,Joyce O’Shaughnessy,Peter A. Fasching,Zhi-Min Shao,Delphine Loirat,Y.H. Park,María Ángeles Fernández,Z. Liu,Hiroyuki Yasojima,Yu Ding,L. Jia,Vassiliki Karantza,Konstantinos Tryfonidis,Aditya Bardia	2023	67
6	Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study Clinical Cancer Research ·Sara M. Tolaney,Kevin Kalinsky,Virginia Kaklamani,David R. D’Adamo,Gursel Aktan,Michaela L. Tsai,Ruth O’Regan,Peter A. Kaufman,Sharon Wilks,Eleni Andreopoulou,Debra A. Patt,Yuan Yuan,Grace Wang,Claudio Savulsky,Dongyuan Xing,Ella Kleynerman,Vassiliki Karantza,Sami Diab	2021	90
7	Prevalence, treatment patterns, and prognosis of low estrogen receptor-positive (1% to 10%) breast cancer: a single institution’s experience in Korea Breast Cancer Research and Treatment ·Yeon Hee Park,Vassiliki Karantza,Shawna R. Calhoun,Seri Park,Sohee Lee,Ji‐Yeon Kim,Jong Han Yu,Seok Won Kim,Jeong Eon Lee,Seok Jin Nam,Gursel Aktan,Mark Marsico	2021	10
8	Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis Cancer Research ·Min Huang,Joyce O’Shaughnessy,Jing Zhao,Amin Haiderali,Javier Cortés,Scott D. Ramsey,Andrew Briggs,Peter Hu,Vassiliki Karantza,Gursel Aktan,Cynthia Z. Qi,Chenyang Gu,Jipan Xie,Muhan Yuan,John S. Cook,Michael Untch,Peter Schmid,Peter A. Fasching	2020	89
9	68TiP KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) + olaparib (ola) vs pembro + chemotherapy after induction with first-line (1L) pembro + chemo in patients (pts) with locally recurrent inoperable or metastatic TNBC Annals of Oncology ·Shigehira Saji,Antonio Llombart‐Cussac,Fabrice André,Mark E. Robson,Nadia Harbeck,Peter Schmid,David W. Cescon,Jin Seok Ahn,Rita Nanda,L. Fan,Jaime Mejia,Vassiliki Karantza,Aditya Bardia,Hope S. Rugo	2020	2
10	44O Pembrolizumab (pembro) vs chemotherapy (chemo) for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-119 Asia-Pacific subpopulation Annals of Oncology ·S-A. Im,Javier Cortés,Oleg Lipatov,Anthony Gonçalvès,KS Lee,Peter Schmid,Kenji Tamura,Laura Testa,I Witzel,Shoichiro Ohtani,Stefania Zambelli,Nadia Harbeck,Fabrice André,Rebecca Dent,J. Lin,Vassiliki Karantza,Jaime Mejia,Eric P. Winer	2020	4
11	Relationship between tumor infiltrating lymphocytes (TILs) and response to pembrolizumab (pembro)+chemotherapy (CT) as neoadjuvant treatment (NAT) for triple-negative breast cancer (TNBC): Phase Ib KEYNOTE-173 trial Annals of Oncology ·Sherene Loi,Peter Schmid,Gursel Aktan,Vassiliki Karantza,Roberto Salgado	2019	17
12	KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (PBO) + chemo for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC). Journal of Clinical Oncology ·Javier Cortés,Zifang Guo,Vassiliki Karantza,Gursel Aktan	2018	5
13	Abstract P5-15-02: Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer Cancer Research ·SM Tolaney,Claudio Savulsky,Gursel Aktan,D. Xing,A. Almonte,Vassiliki Karantza,Sami Diab	2017	8
14	Phase 2 study of pembrolizumab as first-line therapy for PD-L1–positive metastatic triple-negative breast cancer (mTNBC): Preliminary data from KEYNOTE-086 cohort B. Journal of Clinical Oncology ·Sylvia Adams,Sherene Loi,Deborah Toppmeyer,David W. Cescon,Michelino De Laurentiis,Rita Nanda,Eric P. Winer,Hirofumi Mukai,Kenji Tamura,Anne Armstrong,Minetta C. Liu,Hiroji Iwata,Larisa Ryvo,Pauline Wimberger,Deborah Card,Yu Ding,Vassiliki Karantza,Peter Schmid	2017	55
15	ERBB2 overexpression suppresses stress-induced autophagy and renders ERBB2-induced mammary tumorigenesis independent of monoallelicBecn1loss Autophagy ·Fred Lozy,Xiaofeng Cai-McRae,Irina Teplova,Sandy M. Price,Anupama Reddy,Gyan Bhanot,Shridar Ganesan,Alexei Vázquez,Vassiliki Karantza	2014	35
16	Sequestosome 1/p62 facilitates HER2-induced mammary tumorigenesis through multiple signaling pathways Oncogene ·Xiaofeng Cai-McRae,H. Zhong,Vassiliki Karantza	2014	30
17	Autophagy Opposes p53-Mediated Tumor Barrier to Facilitate Tumorigenesis in a Model of PALB2 -Associated Hereditary Breast Cancer Cancer Discovery ·Yanying Huo,Hong Cai,Irina Teplova,Christian Bowman-Colin,Guanghua Chen,Sandy M. Price,Nicola Barnard,Shridar Ganesan,Vassiliki Karantza,Eileen White,Bing Xia	2013	111
18	Autophagy Regulates Keratin 8 Homeostasis in Mammary Epithelial Cells and in Breast Tumors Molecular Cancer Research ·Sameera Kongara,Olga Kravchuk,Irina Teplova,Fred Lozy,Jennifer Schulte,Dirk F. Moore,Nicola Barnard,Carola A. Neumann,Eileen White,Vassiliki Karantza	2010	41
19	Role of Autophagy in Breast Cancer Autophagy ·Vassiliki Karantza,Eileen White	2007	122
20	Laminin α subunits and their role in C. elegans development Development ·Chengchen Huang,David H. Hall,Edward M. Hedgecock,Gautam Kao,Vassiliki Karantza,Bruce E. Vogel,Harald Hutter,Andrew Chisholm,Peter D. Yurchenco,William G. Wadsworth	2003	116

About Vassiliki Karantza

Vassiliki Karantza is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine, having authored 109 papers that have together received 8.0k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (54 papers), Advanced Breast Cancer Therapies (39 papers), HER2/EGFR in Cancer Research (22 papers), Breast Cancer Treatment Studies (21 papers), Cancer Genomics and Diagnostics (17 papers), Cancer Treatment and Pharmacology (15 papers), Autophagy in Disease and Therapy (12 papers) and Cancer Cells and Metastasis (11 papers). The work is most often cited by research in Oncology (4.7k citations), Cancer Research (2.0k citations) and Immunology (1.8k citations). Vassiliki Karantza has collaborated with scholars based in United States, Spain and Germany. Frequent co-authors include Gursel Aktan, Ning Chen, Eileen White, Peter Schmid, Javier Cortés, Sherene Loi, Lajos Pusztai, Laurence Buisseret, Raanan Berger and Kumudu Pathiraja. Their work appears in journals such as New England Journal of Medicine, Journal of Clinical Oncology and Genes & Development.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact